.Attributes Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) procedure of individuals with HER2+ innovative breast cancer cells and energetic or dependable human brain metastases revealed constant intracranial activity as well as wide spread effectiveness of T-DXd.